Mybiotics Pharma LTD
Dorit Rozner, Ph.D has an extensive work experience in various roles and companies. Dorit is currently a Board Member at Forsea since 2022. Prior to that, they served as the CTO at The Kitchen Hub, starting in 2020.
From 2015 to 2020, Dorit worked at mybiotics Pharma LTD, holding the positions of Head of advanced drug delivery technologies and later CTO. Dorit also worked as a CTO at a start-up company from 2017 to 2018.
Earlier in their career, Dorit was the VP R&D at Vital Technologies Ltd. from 2015 to 2017. Dorit began their career at Lycored in 2006, where they held the role of Director of Market Development for Technology solutions & R&D Manager.
Dorit Rozner obtained their Ph.D. from the Weizmann Institute of Science in 2005. Dorit'sexpertise lies in Microencapsulation technologies of food supplements and nutrition, specializing in formulations, premixes, and various applications for increasing shelf life, preventing oxidation, masking odor and taste, and more.
Dorit Rozner, Ph.D, has a strong educational background in chemistry. Dorit obtained a PhD in organic chemistry with a specialization in catalysis from the Weizmann Institute of Science, where they studied from 2004 to 2006. Dorit further pursued their academic career at the same institute, earning another PhD in organic chemistry from 2000 to 2005. In 2010, Dorit Rozner briefly shifted their focus and studied business management at HAMIL, completing their studies in 2011.
Previous companies
This person is not in any teams
This person is not in any offices
Mybiotics Pharma LTD
MyBiotics innovative technologies; MyCrobeTM and SuperDonorTM allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobeTM and SuperDonorTM provide single or multi-bacterial combinations for targeted treatment, wholemicrobiome restoration and the first actual screening method to replace FMT microbiome transplantations. MyBiotics focus is to return the bacterial population to its healthy and balanced state by using live bacteria that will colonize and compete with the existent disease-promoting population.